Abstract:PD-(L)1 inhibitors have provided new treatment approaches for patients with NSCLC; however, resistance to PD-(L)1 inhibitors or low PD-L1 expression may limit clinical benefit. Tislelizumab, a monoclonal antibody with high affinity and specificity for PD-1, was recently approved in China for the treatment of previously treated classical Hodgkin lymphoma. Tislelizumab was engineered to minimize binding to FcɣR on macrophages to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti- PD-1 therapy. Preliminary reports from this study (NCT04068519) showed that tislelizumab monotherapy was generally well tolerated and demonstrated antitumor activity in Chinese patients with advanced solid tumors. We now present data from patients with NSCLC. This multi-arm, open-label, nonrandomized phase 1/2 study evaluated safety/tolerability, antitumor activity, and survival in patients with histologically/cytologically confirmed advanced solid tumors treated with tislelizumab. Eligible patients progressed on, or were intolerant to, their last standard antitumor treatment and were anti-PD-(L)1 therapy treatment-naïve. Patients received intravenous tislelizumab 200 mg every 3 weeks until loss of clinical benefit or unacceptable toxicity. Patients were considered PD-L1-positive if ≥10% of their tumor cells had PD-L1 membrane staining at any intensity using the VENTANA PD-L1 (SP263) assay. Antitumor response was assessed by RECIST v1.1, overall survival (OS) was estimated by Kaplan-Meier analysis, and safety/tolerability was examined by monitoring adverse events (AEs). As of 01 December 2018, 56 patients with NSCLC (nonsquamous, n=31 [55%]; squamous, n=25 [45%]) were enrolled. Forty patients (71%) were male, 53 (95%) had metastatic disease, and 23 (41%) had never smoked; one patient each had an EGFR mutation or ALK rearrangement. Patients were heavily pretreated, with 16 patients (29%) receiving ≥3 lines of prior systemic therapy. The most common treatment-related AEs (TRAEs) were increased AST (n=14; 25%), increased ALT (n=13; 23%), and rash (n=8; 14%). Increased AST (n=3; 5%) and increased ALT (n=2; 4%) were the only grade ≥3 TRAEs occurring in ≥2 patients. Immune-related AEs (irAE) were reported in 12 patients (21%) and were generally of low severity, including 1 patient with grade 2 pneumonitis; 4 patients (7%) experienced a grade ≥3 irAE. The objective response rate (ORR) was 18% (95% CI: 8.9, 30.4), with an ORR of 17% (95% CI: 4.7, 37.4) and 19% (95% CI: 7.5, 37.5) in patients who were PD-L1-positive (n=24) and PD-L1-negative (n=31), respectively. With a median follow-up of 14.6 months (95% CI: 12.0, 15.6), median OS was not reached in patients with NSCLC. Updated data with a follow-up of ≥2 years will be presented, including OS. Tislelizumab was generally well tolerated and demonstrated antitumor activity in NSCLC patients regardless of PD-L1 expression status. Tislelizumab is being evaluated as a single agent or with chemotherapy in phase 3 studies in NSCLC patients (NCT03358875, NCT03594747, and NCT03663205).

75P PD-L1 Expression and TMB Guided First-Line Sintilimab Monotherapy for Advanced NSCLC in a Multi-Center, Phase II Umbrella Trial (CTONG 1702)

Assessment of TMB, PD-L1, and lymphocyte to monocyte ratio as predictive potential in a phase Ib study of sintilimab in patients with advanced solid tumors

P17.02 RATIONALE 307: A Subgroup Analysis of Tislelizumab Plus Chemo Vs Chemo Alone As 1L Treatment for Stage IIIB Advanced Sq NSCLC

Phase Ib Study of Sintilimab in Combination with Chemotherapy for 1L Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).

LBA57 MHC-II Antigen Presentation Pathway As a Predictive Biomarker for Sintilimab Plus Chemotherapy in First-Line Treatment of Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (Nsq-Nsclc)

1263P Tislelizumab + Chemotherapy Vs Chemotherapy Alone As First-Line Treatment for Locally Advanced/metastatic Nonsquamous NSCLC

LBA56 ORIENT-12: Sintilimab Plus Gemcitabine and Platinum (GP) As First-Line (1L) Treatment for Locally Advanced or Metastatic Squamous Non-Small-cell Lung Cancer (Sqnsclc)

Safety and efficacy of sintilimab in combination with SBRT and LDRT in PD-L1 positive treatment naïve-stage IV non-small cell lung cancer: A phase I study (IHC study).

A Multi-Center Phase II Study of Toripalimab with Chemotherapy in Patients with EGFR Mutant Advanced NSCLC Patients Resistant to EGFR TKIs: Efficacy and Biomarker Analysis.

Safety and Tolerability Evaluation of Sintilimab in Combination with Low Dose Radiation and SBRT in Treatment Naive Stage IV PD-L1 Positive NSCLC Patients

86P Efficacy and Safety of IBI110 (Anti-Lag-3 Mab) in Combination with Sintilimab (Anti-Pd-1 Mab) in Advanced Squamous Non-Small Cell Lung Cancer (sqnsclc): Updated Results of the Phase Ib Study

OA07.09 Sintilimab in Combination with Anlotinib as First-Line Therapy for Advanced NSCLC: Final Analysis of Primary Endpoints

1264P Updated Analysis of Tislelizumab Plus Chemotherapy Vs Chemotherapy Alone As First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer (SQ NSCLC)

TS01.03 Efficacy and Safety Data from a Phase 1/2 Trial of Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC)

Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small-Cell Lung Cancer Patients

Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non-Small Cell Lung Cancer Patients

P2.04-29 Preliminary Results with Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC)

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC.

Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker.

P1.04-02 Efficacy and Safety of Sintilimab with Anlotinib As First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)